These payloads alter how tightly genetic instructions are packaged and used. Researchers have attached them to antibodies to test targeted control of cancer-cell behavior.
Cetuximab conjugates carrying the histone deacetylase inhibitor ST7612AA1 were studied with cleavable and non-cleavable linkers. The primary report demonstrated changes in histone and tubulin acetylation and antitumor activity in animal models. This supports an epigenetic payload concept even when the unconjugated molecule is less cytotoxic than conventional payloads. Human safety and benefit require separate evaluation.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/